![Hugh Jackson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Hugh Jackson
Director/Miembro de la Junta en Actimed Therapeutics Ltd. .
Cargos activos de Hugh Jackson
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Actimed Therapeutics Ltd.
![]() Actimed Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education. | Director/Miembro de la Junta | - | - |
Director Financiero/CFO | - | 19/10/2023 |
Historial de carrera de Hugh Jackson
Estadísticas
Internacional
Reino Unido | 2 |
Operativa
Director/Board Member | 1 |
Director of Finance/CFO | 1 |
Sectorial
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Actimed Therapeutics Ltd.
![]() Actimed Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education. | Commercial Services |
- Bolsa de valores
- Insiders
- Hugh Jackson
- Experiencia